For the roughly 70,000 to 80,000 adults in the United States living with chronic hypoparathyroidism, daily life revolves around a punishing regimen: handfuls of calcium pills, multiple doses of active vitamin D, and the constant threat that a missed dose could send blood calcium plummeting, triggering muscle spasms, tingling, seizures, or worse. The condition, most often caused by damage to the parathyroid glands during thyroid or neck surgery, robs the body of its ability to regulate calcium on its own. And for years, the only approved hormone replacement, Natpara, was pulled from the U.S. market in 2019 after a recall tied to rubber particle contamination in its delivery device.
Now, a new PTH-based therapy called eneboparatide has completed a pivotal Phase 3 trial, and the results could reshape treatment for a patient population that has been waiting more than half a decade for a real alternative. The trial, called CALYPSO, reported positive topline data in early 2025, according to its sponsor, and the findings position eneboparatide as a potential second entrant in a therapeutic space that, until recently, had zero available hormone-replacement options in the U.S.
Why this disorder is so hard to live with
The parathyroid glands, four tiny structures behind the thyroid, produce parathyroid hormone (PTH), which acts as the body’s calcium thermostat. PTH pulls calcium from bones when blood levels dip, signals the kidneys to hold onto calcium rather than flush it out, and activates vitamin D so the gut can absorb calcium from food. When those glands are damaged or removed, the entire system collapses.
Standard management relies on large daily doses of calcium carbonate and calcitriol (active vitamin D) to prop up blood calcium levels from the outside. But this approach is blunt. It does nothing to restore the feedback loop that keeps calcium in a narrow, safe range. Over time, the constant calcium loading can cause kidney stones, calcium deposits in soft tissues including the brain, chronic fatigue, and cognitive difficulties that patients often describe as “brain fog.” Many report that the condition dominates their lives in ways that lab values alone do not capture.
What CALYPSO tested
Eneboparatide is a PTH receptor 1 (PTHR1) agonist, meaning it mimics the action of natural parathyroid hormone at the receptor responsible for calcium regulation. A peer-reviewed Phase 1 trial, published in Endocrine Connections, established the drug’s safety, tolerability, and pharmacokinetic profile in humans, confirming that it activates the biological pathway the body normally uses to maintain calcium balance.
The CALYPSO trial, registered on ClinicalTrials.gov, is a Phase 3, randomized, placebo-controlled, double-blind study in adults with chronic hypoparathyroidism. The first 24 weeks are randomized and blinded, the gold-standard design for determining whether a drug truly works compared with placebo. That structure matters because it eliminates the bias that can inflate results in open-label studies, where both patients and doctors know who is receiving the active drug. After the blinded portion, participants can continue in an extension phase to allow investigators to observe longer-term calcium control and safety.
The trial’s design follows the composite endpoint approach established by the PaTHway trial, a separate Phase 3 study that tested TransCon PTH, now marketed as Yorvipath. In PaTHway, investigators measured whether patients could maintain normal blood calcium while substantially reducing or eliminating their dependence on supplements. Results published in the Journal of Bone and Mineral Research showed that many participants achieved stable calcium levels with far lower doses of oral calcium and calcitriol. That composite standard has become the benchmark for what meaningful improvement looks like in hypoparathyroidism: not just better numbers on a lab report, but genuine reduction in the pill burden that defines daily life.
The competitive landscape
Yorvipath, developed by Ascendis Pharma, received FDA approval based on its PaTHway data. The agency’s drug trials snapshot documents the participant demographics and key evidence behind the decision. That approval was a landmark: it gave U.S. patients their first available PTH-based therapy since Natpara’s withdrawal and established a regulatory precedent showing the FDA will clear hormone-replacement treatments for hypoparathyroidism when trial data demonstrate both calcium normalization and supplement reduction.
Eneboparatide would enter a market where Yorvipath is currently the only approved PTH replacement in the U.S. The two drugs target the same receptor but differ in molecular design, dosing schedule, and pharmacokinetic profile. For patients and endocrinologists, having a second option could matter significantly. Competition tends to improve access, drive down costs, and give clinicians flexibility to match a therapy’s characteristics to an individual patient’s needs and preferences.
No head-to-head trial comparing eneboparatide with Yorvipath exists in the public record. Without that direct comparison, any claim of superiority from either side would be speculative. Patients and clinicians will eventually need comparative data to make fully informed treatment decisions, but for now the evidence supports only the conclusion that both drugs aim at the same biological target through different engineering approaches.
What we still don’t know
Despite the positive topline signal, detailed outcome data from CALYPSO have not yet appeared in a peer-reviewed journal. Specific numbers, such as the percentage of patients who achieved normal calcium levels or the proportion able to stop taking supplements entirely, remain unavailable for independent scrutiny. Until those data are published, the strength of eneboparatide’s performance can be described in terms of trial design and the sponsor’s characterization, but not fully evaluated on the merits.
Long-term safety data are also limited. The randomized portion of CALYPSO covers 24 weeks, long enough to detect whether the drug works but too short to reveal complications that might emerge over years of continuous use. PTH analogs can affect bone turnover, and any sustained increase in calcium mobilization from bone raises theoretical concerns about skeletal health over time. The Phase 1 trial mapped short-term pharmacodynamics, but whether eneboparatide’s receptor selectivity translates into a favorable long-term safety profile is a question only extended follow-up can answer.
Patient-reported quality-of-life data and demographic breakdowns by race, ethnicity, or sex from CALYPSO are also absent from publicly available documents. The FDA’s Yorvipath snapshot included participant demographics, setting a transparency standard that any future filing for eneboparatide will need to match. Whether CALYPSO enrolled a sufficiently diverse population to support broad conclusions about effectiveness across different groups is unknown based on current public records.
Practical questions loom as well. Eneboparatide would be an injectable therapy, and patients will want to know about injection frequency, device design, storage requirements, and cost. Yorvipath’s list price has drawn attention in the hypoparathyroidism community, and whether a second entrant would offer a more affordable alternative or follow similar pricing remains to be seen.
What this means for patients waiting for options
For a community that watched its only approved hormone replacement disappear from pharmacy shelves in 2019, the progress represented by CALYPSO is significant. Yorvipath’s approval in 2024 broke a long drought, and eneboparatide’s positive Phase 3 signal suggests the treatment landscape may continue to expand.
But cautious optimism is warranted, not uncritical enthusiasm. The full CALYPSO dataset needs to be published and peer-reviewed. Long-term safety monitoring will be essential. And the real-world questions that clinical trials rarely answer, such as insurance coverage, out-of-pocket costs, and how well a new injectable fits into the routines of people already managing a demanding chronic condition, will ultimately determine whether eneboparatide becomes a practical option or an expensive one that only some patients can access.
The science, at least, is moving in the right direction. After years of treating a hormone-deficiency disorder without replacing the missing hormone, the field is finally catching up to what patients have long understood: supplements are a workaround, not a solution. Whether eneboparatide delivers on the promise its trial was designed to test will become clear as the data reach daylight. For the tens of thousands of people managing hypoparathyroidism every day, that transparency cannot come soon enough.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
